Anaemia and Immunological Markers in HIV Patients on Antiretroviral Drugs (HAART)
[1]
Ibrahim A., Department of Medical Laboratory Science, Faculty of Allied Health Sciences Bayero University, Kano, Nigeria.
[2]
Yahaya H., Department of Medical Laboratory Science, Faculty of Allied Health Sciences Bayero University, Kano, Nigeria.
[3]
Gwarzo M. Y., Department of Medical Laboratory Science, Faculty of Allied Health Sciences Bayero University, Kano, Nigeria.
[4]
Muhammad A. B., Department of Medical Laboratory Science, Faculty of Allied Health Sciences Bayero University, Kano, Nigeria.
[5]
Sharfadi R. S., Department of Medical Laboratory Science, Faculty of Allied Health Sciences Bayero University, Kano, Nigeria.
Among those with HIV, anaemia is a strong risk factor for disease progression and death independent of CD4 count. This study is aimed at evaluating the effect of ARV drugs on anaemia and immunological markers in HIV patients. A total of forty four patients placed on HAART (Niverapine + Stavudine/Zidovudine + Lamivudine) were enrolled for the study. CD4 cell count was done using Becton Dickinson (BD) FACSCount analyser, while platelets, lymphocytes%, neutrophils%, and Haemoglobin (Hb) were determined using QBC Autoread analyser. All the parameters were repeated at 12th week and 24th week after placement on drug regimen. The mean CD4 cells count was 198.26 cells/µl, 240.37 cells/µl and 360.45 cells/µl for baseline, 12th and 24th week respectively. Total WBC count was 7.62x109 /L, 7.3x109 /L and 7.39 x109 /L, while lymphocytes% count was 39.2%, 43.2% and 43.2%. The neutrophils% count was 58.8%, 39.7% and 59.7%. The platelets count was 29.5 x109 /L, 303.6 x109 /L and 286 x109 /L (Values represent baseline 12th week and 24th week respectively). Results between baseline and 12th week, CD4, Hb, and WBC count showed significant increase (P<0.05) as well as 12th and 24th week CD4, Hb and ESR, showed significant increase. It was concluded that HAART results in improved in immunological response and reduces incidence of anemia in HIV/AIDS patients.
HAART, CD4, Baseline, BD FACSCount, Regimen
[1]
Ballah A. D., Ibrahim M. K. Ahmed, H., Ayuba, D., and Muhammed, A. S. (2013): prevalence of Anaemia and Immunological Markers in HIV – infected patients on HAART in Northeastern, Nigeria.
[2]
Cheesbrough M; (2004): District Laboratory Practice in Tropical Countries (part 2), Cambridge University Press PP 254 – 255.
[3]
Hammer, S., Squires, K., Hughes, M. (1997): A controlled trial of two nucleoside analogues plus indinavir in persons with HIV infection and CD 4 cell count of 200/cubic millimeter (cm3) or less. N. Engl. J. of Med. 337: 725 – 733.
[4]
Olayemi, E., Awodu, O. A. and Bazuaye, G.N. (2008): Autoimmune Hemolytic Anemia in HIV infected patients: A Hospital Based Study. Annals of African Medicine Vol. 7: No. 2, PP 72.
[5]
Volberding, P. (2002): The impact of anemia on quality of life in HIV infected patients. J. Infect. Dis. 185 (Suppl 2): S110 – S114.
[6]
William, E. P. (2003): “Fundamental Immunology” fifth edition, Lippincott Williams and Wilkins (Publishers), Pg 1292.
[7]
Kirchhoff, F. and Silvestri, G. 2008): J Clin Invest 118: 1622–5.
[8]
UNAIDS (2010): Getting to Zero: 2011–2015 UNAIDS Strategy.
[9]
WHO author, AIDS epidemic update: December 2004: Geneva, Pg 87.
[10]
International Planned Parenthood Foundation (2009): The truth about men, boys and sex: Gender transformative policies and programmes.
[11]
José Alberto, Arranz Caso, Cristina Sanchez Mingo, Jaime Garcia Tena. (1999): The New England Journal of Medicine, 341: 1239 –1240.
[12]
Ramana, K. B. (2013): “Markers of HIV disease progression of HIV – 1 and treatment response in HAART”. American Journal of Infectious Diseases and Microbiology Volume 1 Pp 84 – 105.
[13]
Ghana AIDS Commission, (2001): author, Ghana HIV/AIDS strategic framework: 2001–2005. Accra, Ghana: Ghana AIDS Commission.
[14]
Amornkul, P.N., Vandenhoudt, H., Nosokho, P., Odhiambo, F., Mwaengo, D., Hightower, A., Buve, A., Misore, A., Volule, J., Vitek, C., Glynn, J., Greenberg, A., Slutsker, L., and De CockK.M. (2009): HIV prevalence and associated risk factors among individual aged 13 – 34 years in Rural Western Kenya 4(7): 6470.
[15]
Okolie, MN, Eghafona, NO, Omerigie R, (2003): Anti- human Immunodeficiency virus agents. Journal of Medical Laboratory Science, 12: 1 – 14.
[16]
Owiredu, WKBA, Quaye, L., Amidu, N., Addai- mensah, O. (2011): Prevalence of Anaemia and Immunological Markers among Ghanian HAART – naïve HIV patients and those on HAART. Afr Health Science 11(1): 2 – 15.
[17]
Janet, E., Marry Z., Gearge, L.R., ALIEN, B., Paul Racz., Klara, T. and Ashli, T. H. (1993): “Massive covert infection of Helper T – lymphocyte and macrophages by HIV during the incubation period of AIDS”. Nature 362: 359 -362.
[18]
McCune, JM. (2001): The dynamics of CD4+ T-cell depletion in HIV disease. Nature 410:974-979
[19]
Semba, RD., Shah N and Vlahov D. (2001): Improvement of anaemia among HIV infected injection drug users receiving highly active antiretroviral therapy. Journal of acquired Immune Deficiency Syndrome. 26: 315-19.
[20]
Bernstein, ZP., Gworek, MA and Small, BM. (1989): Hematologic abnormalities in patients with acquired immunodeficiency syndrome. Journal of Medicine. 20:177-92
[21]
Jacobson, MA, Perepere, L, Volberdin, PA, Porteoenus, D, Toy, PT and Feigal, D (1990): Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence associated factors, and outcome. Transfusion. 30:133-7
[22]
Koka, PS, Jamieson, BD, and Brooks DG, (1999): HIV-1 induced hematopoietic inhibition is independent of productive infection of projenitor cells in vivo. Journal of Virology. 73:9089-97.
[23]
Bahner, I, Kerans, K, and Coutinho, S. (1997): Infection of human marrow stroma by HIV-1 is both required and sufficient for HIV-1 induced haematopoietic suppression in vitro: demonstration by gene modification of primary human stroma. Blood. 90:1787-98.
[24]
Becton, D. (2008): BD FACSCount System User’s guide. 12-76
[25]
Becton, D. (2008): QBC Autoread haematology system user’s guide. 5-1, 7-3.
